Good Response, as it scoops up Pathwork
This article was originally published in Clinica
Executive Summary
Response Genetics’ share price witnessed a 27% boost after the firm announced the acquisition of “all of the key assets” of molecular diagnostic rival Pathwork Diagnostics for $200,000 cash and 500,000 shares. Redwood City, California-based Pathwork went out of business in April.